Use of cellular HIV DNA to predict virologic response to maraviroc: Performance of population-based and deep sequencing

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1659-1666

  Swenson, Luke C ^a   Dong, Winnie W Y ^a   Mo, Theresa ^a   Demarest, James ^b   Chapman, Doug ^c   Ellery, Suzanne ^d   Heera, Jayvant ^d   Valdez, Hernan ^c   Poon, Art F Y ^a   Harrigan, P Richard ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b VIIV HEALTHCARE   (United States)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

HIV coreceptor usage tropism; HIV proviral DNA; maraviroc; next generation sequencing

Indexed keywords

MARAVIROC; VIRUS DNA; VIRUS RNA;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DNA SEQUENCE; FALSE POSITIVE RESULT; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; VIRAL TROPISM; VIRUS LOAD;

HIV CORECEPTOR-USAGE/TROPISM; HIV PROVIRAL DNA; MARAVIROC; NEXT-GENERATION SEQUENCING;

CYCLOHEXANES; DNA, VIRAL; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTES, MONONUCLEAR; TREATMENT OUTCOME; TRIAZOLES; VIRAL TROPISM;

EID: 84877255753     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit105     Document Type: Article

References (38)

1. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-41.
2. Lalezari J, Gathe J, Brinson C, et al. Safety, efficacy, and pharmacoki-netics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr 2011; 57:118-25.
3. Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009; 200:1724-8.
4. Saag M, Goodrich J, Fätkenheuer G, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199:1638-47.
5. Cooper D, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of anti-retroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803-13.
6. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24:2517-25.
7. Swenson LC, Mo T, Dong WWY, et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203:237-45.
8. Swenson LC, Mo T, Dong WWY, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53:732-42.
9. Lalezari J, Mitsuyasu R, Deeks S, et al. Successful and persistent en-graftment of ZFN-M-R5-D autologous CD4 T cells (SB-728-T) in aviremic HIV-infected subjects on HAART. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 27 February-2 March 2011. Abstract 46.
10. Ando D, Tang WW, Stein D. HAART treatment interruption following adoptive transfer of zinc finger nuclease (ZFN) modified autologous CD4 T-cells (SB-728-T) to HIV-infected subjects demonstrates durable engraftment and suppression of viral load. In: 51st Inter-science Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17-20 September 2011. H2-794a.
11. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
12. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-8.
13. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.
14. El-Sadr W, Lundgren JD, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
15. Soulié C, Fourati S, Lambert-Niclot S, et al. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010; 65: 749-51.
16. Swenson LC, Moores A, Low AJ, et al. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 2010; 54:506-10.
17. Kuritzkes DR. Genotypic tests for determining coreceptor usage of HIV-1. J Infect Dis 2011; 203:146-8.
18. Sing T, Low AJ, Beerenwinkel N, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007; 12:1097-106.
19. McGovern RA, Dong W, Mo T, et al. Optimization of clinically relevant cutpoints for the determination of HIV coreceptor usage to predict maraviroc responses in treatment experienced (TE) patients using population V3 genotyping. In: European AIDS Clinical Society, Cologne, Germany, November 11-14, 2009. Poster PE3.4/8.
20. Swenson LC, McGovern RA, Dong W, et al. Optimization of clinically relevant cutoffs for determining HIV coreceptor use by population and deep sequencing methods. In: Infectious Diseases Society of America 47th Annual Meeting, Philadelphia, Pennsylvania October 29-November 1, 2009.
21. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-55.
22. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-33.
23. Vandekerckhove L, Wensing A, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11:394-407.
24. Kirby Institute, ViiV Healthcare, Pfizer. Maraviroc Switch Collaborative Study (MARCH), 2012. Available at: http://clinicaltrials.gov/ct2/show/ NCT01384682. Accessed 30 January 2012.
25. Vitiello P, Brudney D, MacCartney M, et al. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load. Intervirology 2012; 55:172-8.
26. Prosperi MCF, Bracciale L, Fabbiani M, et al. Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 2010; 7:56.
27. Verhofstede C, Brudney D, Reynaerts J, et al. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011; 12:544-52.
28. Paar C, Geit M, Stekel H, Berg J. Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J Clin Mi-crobiol 2011; 49:2697-9.
29. Parisi SG, Andreoni C, Sarmati L, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol 2011; 49:1441-5.
30. Waters LJ, Scourfield AT, Marcano M, et al. The evolution of corecep-tor tropism in HIV-infected patients interrupting suppressive antire-troviral therapy. Clin Infect Dis 2011; 52:671-3.
31. Lee GQ, Dong W, Mo T, Woods C, Kanters S, Shen A. Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy. In: Infectious Diseases Society of America. Vancouver, BC, Canada, October 21-24, 2010. Abstract 3646.
32. Abbate I, Rozera G, Tommasi C, et al. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect 2011; 17:725-31.
33. Verhofstede C, Vandekerckhove L, Eygen VV, Vandenbroucke I, et al. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009; 50:126-36.
34. Baldanti F, Paolucci S, Gulminetti R, et al. Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART. Antiviral Res 2001; 50:197-206.
35. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 2011; 108:20166-71.
36. Andreoni M, Parisi SG, Sarmati L, et al. Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active an-tiretroviral therapy. AIDS (London, England) 2000; 14:23-9.
37. Sarmati L, Parisi SG, Nicastri E, et al. Association between cellular human immunodeficiency virus DNA level and immunologi-cal parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol 2005; 43: 6183-5.
38. Schapiro JM, Boucher CA, Kuritzkes DR, et al. Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther 2011; 16:395-404.